Liver disease imposes a significant healthcare burden, causing approximately 2 million deaths globally each year, accounting for 4% of all deaths. Regardless of its cause, repetitive liver damage leads to progressive fibrosis, disrupting hepatic architecture, regeneration potential, and overall liver function. Current treatment options for chronic liver disease are limited to addressing the underlying cause or resorting to liver transplantation. Despite numerous anti-fibrotic drug candidates reaching clinical trials, an approved antifibrotic therapy remains elusive.Connected servicesMore informationSpeak to an expert
The activation of liver-resident mesenchymal cells (hepatic stellate cells) into scar-producing myofibroblasts is central to liver fibrosis progression. Understanding the pathogenic signals and cellular interactions within the fibrotic niche is crucial for developing novel antifibrotic therapies that target this pathogenic process.
Concept Life Sciences provides in vitro assays and ex vivo tissue analysis capabilities to facilitate the discovery of new antifibrotic therapies:
Immunology Expertise: Our proficient team of immunologists supports a wide array of services, including in vitro immunology assays that model critical aspects of inflammatory and fibrotic processes.
Cell-Based Assays: Evaluate hepatic stellate cell and myofibroblast function in monoculture and co-culture assays, measuring cell activation, collagen production, migration, and proliferation among other key parameters.
3D Spheroid Liver Fibrosis Models: Test the effectiveness of your antifibrotic therapies using customized hepatocyte and hepatic stellate cell 3D models in immune cell co-culture.
Spatial Biology: Utilize our comprehensive suite of GCP-compliant Histology services and integrated image analysis to aid in target validation, biomarker assay development, and deepen your comprehension of anti-fibrotic drug response and mechanisms of action.